Table 1.
Summary of IHC TMA Patient Cohort
| Parameter | Cohort | Total |
|---|---|---|
| Tumor stage | ||
| Tis | 4 | 163 |
| T1 | 73 | |
| T2 | 61 | |
| T3 | 9 | |
| T4 | 9 | |
| NA | 7 | |
| Node stage | ||
| N0 | 68 | 163 |
| N1 | 37 | |
| N2 | 15 | |
| N3 | 17 | |
| NX | 11 | |
| NA | 15 | |
| Biomarker | ||
| ER | 16 | 108 |
| HER2 | 28 | |
| TNBC | 64 | |
| Histologic diagnosis | ||
| DCIS | 9 | 163 |
| IDC | 137 | |
| ILC | 7 | |
| Medullary | 2 | |
| Metaplastic | 1 | |
| Mucinous | 3 | |
| Papillary | 1 | |
| NA | 3 | |
DCIS, ductal carcinoma in situ; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IDC, infiltrating ductal carcinoma; IHC, immunohistochemistry; ILC, infiltrating lobular carcinoma; NA, not available; Tis, in situ; TMA, tissue microarray; TNBC, triple-negative breast cancer.